Dr. Vogelzang Discusses Cabozantinib's Dose Size | OncLive

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29, 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.


x